WallStreetZenWallStreetZen

NYSE: BMY
Bristol Myers Squibb Co Earnings & Revenue

Open Broker Account
OverviewForecastEarnings
DividendOwnership

BMY past earnings growth

How has BMY's earnings growth performed historically?
Company
N/A
Industry
53.02%
Market
53.18%
BMY's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
BMY's earnings have grown slower... subscribe to Premium to read more.
Earnings Growth vs Market Performance

BMY past revenue growth

How has BMY's revenue growth performed historically?
Company
6.22%
Industry
19.06%
Market
113.02%
BMY's revenue has grown faster... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
BMY's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
BMY's revenue growth is slowing... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

BMY earnings and revenue history

Current Revenue
$47.1B
Current Earnings
$6.6B
Current Profit Margin
14%
BMY's has not demonstrated consistent... subscribe to Premium to read more.
Long-term Earnings Growth Trend Performance

BMY Return on Equity

Current Company
19.3%
Current Industry
41.5%
Current Market
25.7%
BMY's Return on Equity (19.3%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when BMY announces earnings.

BMY Return on Assets

Current Company
6.2%
Current Industry
10.3%
BMY is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

BMY Return on Capital Employed

Current Company
9.62%
Current Industry
15.9%
BMY's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

BMY vs General Drug Manufacturer Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
BMY$47.14B$18.11B$6.62B+18.43%+1.88%
NVS$52.79B$21.56B$22.98B+1.41%+30.20%
AZN$44.04B$7.12B-$1.25B+15.16%N/A
AMGN$26.38B$12.12B$6.58B+2.74%+1.36%
SNY$42.46B$11.96B$6.71B+1.30%-7.60%
View Top General Drug Manufacturer Stocks

BMY earnings dates

Next earnings date
Oct 26, 2022

Bristol Myers Squibb Co Earnings & Revenue FAQ

What were BMY's earnings last quarter?

On Invalid Date, Bristol Myers Squibb Co (NYSE: BMY) reported Q2 2022 earnings per share (EPS) of $0.67, up 42.55% year over year. Total Bristol Myers Squibb Co earnings for the quarter were $1.42 billion. In the same quarter last year, Bristol Myers Squibb Co's earnings per share (EPS) was $0.47.

If you're new to stock investing, here's how to buy Bristol Myers Squibb Co stock.

What was BMY's earnings growth in the past year?

As of Q4 2022, Bristol Myers Squibb Co's earnings has grown year over year. Bristol Myers Squibb Co's earnings in the past year totalled $6.62 billion.

What is BMY's earnings date?

Bristol Myers Squibb Co's earnings date is Invalid Date. Add BMY to your watchlist to be reminded of BMY's next earnings announcement.

What was BMY's revenue last quarter?

On Invalid Date, Bristol Myers Squibb Co (NYSE: BMY) reported Q2 2022 revenue of $11.89 billion up 1.57% year over year. In the same quarter last year, Bristol Myers Squibb Co's revenue was $11.70 billion.

What was BMY's revenue growth in the past year?

As of Q4 2022, Bristol Myers Squibb Co's revenue has grown 6.22% year over year. This is 12.84 percentage points lower than the US Drug Manufacturers - General industry revenue growth rate of 19.06%. Bristol Myers Squibb Co's revenue in the past year totalled $47.14 billion.
©2022 WallStreetZen
Company
AboutBlogPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContact
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market Industries
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
Social
TwitterYouTube
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.